|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Renovo Announces The Appointment Of Dr. David W Feigal Junior, MD, MPH, To The Board Of Renovo Ltd.
10/19/2005 5:11:25 PM
Renovo today announced the appointment of Dr David W Feigal Jnr, MD, MPH as a Non-Executive Director to the Board of Renovo Limited. Dr Feigal was, until May of this year, the Director of the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA), USA. Dr Feigal is a very experienced and knowledgeable regulatory scientist with 12 years of executive experience in 3 FDA product centres. Prior to his appointment as the Director of CDRH in 1999, Dr Feigal was Medical Deputy Director of the FDA’s Center for Biologics Evaluation and Research, where he focussed on blood and tissue products. Previously he served as Director of the Divisions of Antiviral and of Anti Infective Drug Products and the Director of the Office of Drug Evaluation IV, whose remit includes the evaluation of drugs for wound healing applications that employed antimicrobial strategies. His tenure in this position was marked by rapid progress in AIDS therapeutics, expanded access programmes and accelerated approvals. As Director of CDRH he was an advocate for the Center’s Science and Education Programmes.
Prior to joining the FDA, Dr Feigal had a distinguished academic career at the Universities of California, San Francisco and San Diego. His research interests include: clinical epidemiology, clinical trials methodology and he was the Principal Investigator in the studies that lead to the approval of aerosolised Pentamidine, a drug device combination which was one of the earliest therapies for AIDS. Dr Feigal was educated at the University of Minnesota (BA), Stanford University Medical School (MD) and the University of California, Berkley (MPH).
Following his departure from the FDA at the end of April 2004, Dr Feigal has joined NDA Partners LLC.
|
|
|
|
|
|
|
|
|
|
|